Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

All serious fungal infections need appropriate antifungal therapy for successful patient
outcome. Only a few classes of antifungal drugs are available, so the emergence of …

The need for new antifungal agents is undeniable. Current therapeutic choices for the
treatment of invasive fungal infections are limited to three classes of drugs. Most used …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

The epidemiology of Candida infections has changed in recent years. Although Candida
albicans is still the main cause of invasive candidiasis in most clinical settings, a substantial …

Background. Fluconazole (FLC) resistance is common in C. glabrata and echinocandins are
often used as first-line therapy. Resistance to echinocandin therapy has been associated …

Antifungal resistance continues to grow and evolve and complicate patient management,
despite the introduction of new antifungal agents. In vitro susceptibility testing is often used …

Invasive fungal infections are an important infection concern for patients with underlying
immunosuppression. Antifungal therapy is a critical component of patient care, but …

The genus Candida includes about 200 different species, but only a few species are human
opportunistic pathogens and cause infections when the host becomes debilitated or …

Fungal endophytes residing in the internal tissues of living plants occur in almost every plant
on earth from the arctic to the tropics. The endophyte–host relationship is described as a …